Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that repeated oral intake of 0.5 or 5 mg/kg of cobalt ferrite nanoparticles induced pulmonary toxicity in rats, with dose-dependent oxidative stress and inflammation observed, but no notable toxicity was seen at a 0.05 mg/kg dose.

This study found that combining micro-needling, low-level laser therapy, and autologous non-activated platelet-rich plasma increased hair density in patients with androgenic alopecia over the treatment period.

This review discusses recent therapeutic advances in treating various types of hair loss, including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and hair transplant technologies, but reports no new clinical results.

This review discusses emerging targets for developing drugs to treat hair loss and reports no new clinical results; the authors emphasize the potential for therapies that regenerate hair follicles.

This study reports that polyphenols from Annurca apples may safely promote hair growth and protect against chemotherapy-induced alopecia without interfering with chemotherapy regimens.

This review highlights the pharmaceutical potential of secondary metabolites from Juniperus species, noting promising antitumor, antibacterial, and antiviral activities, but reports no new experimental findings.

This review discusses how inflammation influences hair follicle stem cell activities like wound healing and follicle cycling and suggests a potential link between inflammation, stem cell activation, and programmed cell death.

This study concludes that phospholipid–polymer hybrid nanoparticles may be an effective delivery system for quercetin in treating androgenic alopecia by improving hair regrowth and preventing hair follicle cell apoptosis in rat models.

This review analyzes the impact of different preparation methods for platelet-rich plasma, human follicles stem cells, and adipose-derived stem cells on hair regrowth and wound healing, but reports no new results; the authors emphasize convincing evidence of positive outcomes despite protocol variability.

This article discusses the social and psychological impact of hair disorders and the challenges in their treatment, but reports no new clinical results.

This review discusses the potential use of platelet-rich plasma for treating alopecia areata but reports no new experimental findings, noting the need for standardized protocols and larger studies to evaluate its efficacy.

This review discusses current and emerging medical therapies for androgenetic alopecia but reports no new clinical findings, emphasizing the importance of stabilizing the condition as a complement to surgical hair restoration.

This review discusses the emerging pathophysiological factors and potential new therapies for androgenetic alopecia beyond traditional treatments, but reports no new results.

This study found that α-13′-carboxychromanol significantly accelerated wound healing and improved tissue quality in a mouse model, especially when delivered with bacterial nanocellulose under diabetic conditions.

This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.

This study used a newly validated method to find that one-year finasteride treatment resulted in no significant differences in urinary androgen and prostaglandin levels between male pattern baldness patients and normal controls.

This review explores the mechanism and potential applications of wound-induced hair follicle neogenesis but reports no new clinical results, highlighting the need for further research in hair regeneration therapies.

High MUC-18/MCAM levels in blood indicate a worse outlook for melanoma patients.

This review found that oral and topical phosphodiesterase inhibitors and topical prostaglandin analogues are safe and effective treatments for various skin diseases, including psoriasis, atopic dermatitis, vitiligo, and alopecia.

The researchers observed that normal murine hair follicles are direct targets for melatonin, with receptor expression varying throughout the hair cycle, suggesting melatonin's role in hair cycle control.

This abstract explains that androgenetic alopecia, a common hair loss disorder influenced by genetics and hormones like dihydrotestosterone, has FDA-approved treatments including minoxidil, finasteride, and photolaser therapy, but its genetic basis and susceptibility to environmental factors remain complex.

This study found that activating the Nrf2 pathway in human mast cells effectively suppresses degranulation and inflammation induced by substance P.

This study found that inhibiting the interaction between CXXC5 and Dishevelled could stimulate hair regrowth in mouse models by enhancing WNT/β-catenin signaling, suggesting a potential therapeutic strategy for hair loss involving compounds that block this interaction, such as interfering short peptides.

This review identifies several off-label uses of H-1 antihistamines in dermatology beyond itch and urticaria control, though the evidence is weak and further trials are needed.

This review summarizes recent therapeutic advancements in treating various forms of alopecia, including new applications of oral minoxidil, dutasteride, finasteride, Janus kinase inhibitors, and novel hair transplant techniques, without presenting original research results.

No genetic link between prostaglandins and hair loss found.

In this study, researchers identified 32 differentially expressed genes involved in androgenetic alopecia, with down-regulated genes associated with Wnt and TGF-beta signaling and up-regulated genes linked to oxidative stress pathways.

This study found that the distribution of mast cell prostaglandin d-synthase in the scalp spatially aligns with the pattern of androgenetic alopecia, suggesting a programmed vulnerability to hair loss.

This study reported that weekly intramuscular dexpanthenol may improve quality of life and satisfaction with hair appearance in women with female pattern hair loss, with no side effects observed.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.